AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17695436 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CF: cisplatin and 5-fluorouracil)
Number of subjects: 180
Study 17695436 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan or taxane-based regimens
Number of subjects: 180
Study 16121218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimen including mitoxantrone plus cytarabine, two consolidation courses, one with timed-sequential high-dose cytarabine, asparaginase and amsacrine.
Number of subjects: 341
Study 16121218 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic bone-marrow transplantation (allo-BMT) from an HLA-identical sibling in CR1.
Number of subjects: 341
Study 16121218 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy (MT-).
Number of subjects: 341
Study 16121218 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy (MT).
Number of subjects: 341
Study 12100914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 258
Study 12100914 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone, 1 g once a day
Number of subjects: 258
Study 12100914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem and Ceftriaxone
Number of subjects: 258
Study 10100788 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) with best medical therapy
Number of subjects: 634
Study 10100788 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 634
Study 10100788 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) for asymptomatic disease
Number of subjects: 634
Study 7785280 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Volon A
Number of subjects: 40
Study 7785280 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Volon A
Number of subjects: 40
Study 2272190 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release trazodone (150 mg)
Number of subjects: 347
Study 2272190 — intervention group
Group type: COMPARATOR
Intervention: Standard trazodone (150 mg)
Number of subjects: 347
Study 7418410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippes loop
Number of subjects: 841
Study 7418410 — intervention group
Group type: COMPARATOR
Intervention: Copper 7
Number of subjects: 841
Study 7418410 — intervention group
Group type: COMPARATOR
Intervention: Postpartum T
Number of subjects: 841
Study 7418410 — intervention group
Group type: COMPARATOR
Intervention: All three devices
Number of subjects: 841
Study 31368908 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (n=32)
Number of subjects: 97
Study 31368908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (n=32)
Number of subjects: 97
Study 31368908 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=33)
Number of subjects: 97
Study 28039869 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental condition
Number of subjects: 82
Study 28039869 — intervention group
Group type: EXPERIMENTAL
Intervention: Entity condition
Number of subjects: 82
Study 28039869 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 25249191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (8 sessions before discharge and 4 home visits by trained nurses)
Number of subjects: 146
Study 25249191 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 146
Study 23546553 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 467
Study 21190404 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-delivered, mother-daughter intervention
Number of subjects: 546
Study 21190404 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 546
Study 20031847 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM Care by trained pharmacists and pharmacy technicians
Number of subjects: 597
Study 20031847 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 597
Study 20031847 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM Care
Number of subjects: 597
Study 16192451 — intervention group
Group type: EXPERIMENTAL
Intervention: Iseganan
Number of subjects: 709
Study 16192451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study 12653747 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 20% 5-aminolaevulinic acid (ALA) applied 4 hours before illumination with 100 J cm‐2 narrowband red light (630 +/- 15 nm)
Number of subjects: 40
Study 12653747 — intervention group
Group type: COMPARATOR
Intervention: Topical 5-fluorouracil (5-FU) applied to lesions for 4 weeks, with a repeat treatment cycle after 6 weeks if required
Number of subjects: 40
Study 11053909 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (100 mg t.d.s. orally for 5 days)
Number of subjects: 44
Study 11053909 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin sodium (1 g b.i.d. intravenously for 5 days)
Number of subjects: 44
Study 9198569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free surgical treatment
Number of subjects: 64
Study 9198569 — intervention group
Group type: COMPARATOR
Intervention: Shouldice herniorraphy
Number of subjects: 64
Study 8410113 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin-modulated 5-FU (LV + 5-FU)
Number of subjects: 1081
Study 8410113 — intervention group
Group type: COMPARATOR
Intervention: MOF (lomustine, vincristine, and 5-FU)
Number of subjects: 1081
Study 3455938 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CH gel
Number of subjects: 16
Study 3455938 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CH solution
Number of subjects: 16
Study 3455938 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 16
Study 3455938 — intervention group
Group type: COMPARATOR
Intervention: Control site (no irrigation)
Number of subjects: 16
Study 31106666 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab without methotrexate (SWITCH)
Number of subjects: 194
Study 31106666 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab with methotrexate (ADD-ON)
Number of subjects: 194
Study 28639089 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean traditional music (KTM) during surgery
Number of subjects: 52
Study 28639089 — intervention group
Group type: COMPARATOR
Intervention: No Korean traditional music (control) during surgery
Number of subjects: 52
Study 26940720 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 642
Study 26940720 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 642
Study 26940720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 25045152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg genistein provided as a genistein tablet
Number of subjects: 12
Study 25045152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg genistein provided as a genistein tablet in low fat milk
Number of subjects: 12
Study 25045152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg genistein provided as soy milk containing genistein glycosides
Number of subjects: 12
Study 22533447 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate (7·5‐15 mg weekly)
Number of subjects: 478
Study 22533447 — intervention group
Group type: COMPARATOR
Intervention: Etanercept monotherapy
Number of subjects: 478
Study 20809062 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping exercises
Number of subjects: 30
Study 20809062 — intervention group
Group type: COMPARATOR
Intervention: General activity training
Number of subjects: 30
Study 18401809 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 30 Hz and 4 mm amplitude for 60 seconds, repeated twice
Number of subjects: 23
Study 18401809 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 23
Study 18401809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 23
Study 15890314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviourally based stress management intervention (SMI) group
Number of subjects: 209
Study 15890314 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention control group
Number of subjects: 209
Study 16091231 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiretroviral drugs used carefully with an active background regimen
Number of subjects: 0
Study 16091231 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance testing and drug level monitoring
Number of subjects: 0
Study 16091231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-drug regimens
Number of subjects: 0
Study 11690728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (exact dosage not specified)
Number of subjects: 2724
Study 11690728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2724
Study 9325520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (Cytotec)
Number of subjects: 50
Study 9325520 — intervention group
Group type: COMPARATOR
Intervention: Gemeprost (Cervagem)
Number of subjects: 50
Study 7705375 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal degenerative calcification
Number of subjects: 115
Study 7705375 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic calcification
Number of subjects: 115
Study 3601047 — intervention group
Group type: EXPERIMENTAL
Intervention: Left visual half-field presentation of dot arrays
Number of subjects: 0
Study 3601047 — intervention group
Group type: COMPARATOR
Intervention: Right visual half-field presentation of dot arrays
Number of subjects: 0
Study 29861267 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (PA) recommendations and sedentary behavior
Number of subjects: 67
Study 29861267 — intervention group
Group type: COMPARATOR
Intervention: Peak oxygen uptake
Number of subjects: 67
Study 27598553 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive/strengthening exercises combined with manual therapy (mobilizations to influence joint and nerve structures)
Number of subjects: 56
Study 27598553 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive/strengthening exercises
Number of subjects: 56
Study 24866273 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physiotherapy (baseline)
Number of subjects: 39
Study 24866273 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocks of physiotherapy
Number of subjects: 39
Study 24866273 — intervention group
Group type: COMPARATOR
Intervention: Regular physiotherapy
Number of subjects: 39
Study 23538020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe added to maximum tolerated statin therapy
Number of subjects: 2287
Study 23538020 — intervention group
Group type: COMPARATOR
Intervention: Maximum tolerated statin therapy without ezetimibe
Number of subjects: 2287
Study 20655105 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg per day
Number of subjects: 17802
Study 20655105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study 18211506 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free group (n = 112)
Number of subjects: 336
Study 18211506 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal group (n = 115)
Number of subjects: 336
Study 18211506 — intervention group
Group type: COMPARATOR
Intervention: Standard steroids group (n = 109)
Number of subjects: 336
Study 16984076 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-family group treatment (MFGT)
Number of subjects: 97
Study 16984076 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 97
Study 14573327 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive comprehensive educational‐behavioral‐pharmacologic intervention
Number of subjects: 309
Study 14573327 — intervention group
Group type: COMPARATOR
Intervention: Less intensive education and referral intervention
Number of subjects: 309
Study 10920067 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (49±18 mg/d)
Number of subjects: 150
Study 10920067 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (124±55 mg/d)
Number of subjects: 150
Study 10920067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both metoprolol and carvedilol
Number of subjects: 150
Study 8756930 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitacre needle
Number of subjects: 340
Study 8756930 — intervention group
Group type: COMPARATOR
Intervention: Quincke needle
Number of subjects: 340
Study 1551312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metformin infusion
Number of subjects: 9
Study 1551312 — intervention group
Group type: COMPARATOR
Intervention: NaCl infusion (control)
Number of subjects: 9
Study 3551340 — intervention group
Group type: EXPERIMENTAL
Intervention: Forskolin
Number of subjects: 12
Study 3551340 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 12
Study 3551340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30113051 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplements (8 × 10^9 CFU day‐1) for 12 weeks
Number of subjects: 60
Study 27443982 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of children in the home
Number of subjects: 556
Study 24668063 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mixture applied topically three times a day until 1 month postradiation
Number of subjects: 24
Study 24668063 — intervention group
Group type: COMPARATOR
Intervention: Standard care (RadiaPlexRx™ ointment) applied topically three times a day until 1 month postradiation
Number of subjects: 24
Study 22341740 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week training program (controlled physical training)
Number of subjects: 0
Study 22341740 — intervention group
Group type: COMPARATOR
Intervention: No training program (control group)
Number of subjects: 0
Study 19945545 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone supplementation
Number of subjects: 0
Study 19945545 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone supplementation in brain stem death setting
Number of subjects: 0
Study 18377122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 108
Study 18377122 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 108
Study 15693930 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 120
Study 15693930 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 120
Study 15693930 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 120
Study 15693930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12633121 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 0.95 mg/day)
Number of subjects: 345
Study 12633121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 14528573 — intervention group
Group type: EXPERIMENTAL
Intervention: Help card and letter sent to patients before their appointment
Number of subjects: 0
Study 14528573 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not receive the help card)
Number of subjects: 0
Study 7859137 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter health status assessment scales (21 items)
Number of subjects: 1934
Study 7859137 — intervention group
Group type: COMPARATOR
Intervention: Longer health status assessment scales (38 items)
Number of subjects: 1934
Study 1782307 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg/day
Number of subjects: 12
Study 1782307 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 12
Study 1782307 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day
Number of subjects: 12
Study 1782307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7460480 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg three times a day)
Number of subjects: 26
Study 7460480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31237644 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month of DAPT followed by clopidogrel monotherapy
Number of subjects: 3045
Study 31237644 — intervention group
Group type: COMPARATOR
Intervention: 12 months of DAPT with aspirin and clopidogrel
Number of subjects: 3045
Study 29228964 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (2.5 × 10^9 cfu/g) containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58 (Ecologic®Barrier)
Number of subjects: 78
Study 29228964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 26387049 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-Adapted Anger Management Treatment (AM)
Number of subjects: 76
Study 26387049 — intervention group
Group type: COMPARATOR
Intervention: Alcoholics Anonymous Facilitation treatment (AAF)
Number of subjects: 76
Study 25022131 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife therapy
Number of subjects: 60
Study 25022131 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture-cupping
Number of subjects: 60
Study 22115970 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention consisting of self-management training delivered over a 24-month period
Number of subjects: 144
Study 22115970 — intervention group
Group type: COMPARATOR
Intervention: Bilingual newsletter providing identical information
Number of subjects: 144
Study 18771430 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 191
Study 18771430 — intervention group
Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 191
Study 18322604 — intervention group
Group type: EXPERIMENTAL
Intervention: bicyclol combined with thymosin
Number of subjects: 135
Study 15010365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg/d)
Number of subjects: 34
Study 15010365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15010365 — intervention group
Group type: COMPARATOR
Intervention: Alendronate and Placebo
Number of subjects: 34
Study 11588457 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 40
Study 11588457 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 10918156 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave coagulation therapy (14 patients)
Number of subjects: 30
Study 10918156 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy (16 patients)
Number of subjects: 30
Study 10918156 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave coagulation therapy
Number of subjects: 30
Study 10918156 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy
Number of subjects: 30
Study 8791968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nightly
Number of subjects: 74
Study 8791968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily
Number of subjects: 74
Study 8791968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine > or = 2 g daily
Number of subjects: 74
Study 8791968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (general treatment)
Number of subjects: 74
Study 8791968 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 74
Study 8791968 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant disease
Number of subjects: 74
Study 1639051 — intervention group
Group type: EXPERIMENTAL
Intervention: High PUFA diet (20% energy; SAFA and MUFA 10% each)
Number of subjects: 28
Study 1639051 — intervention group
Group type: EXPERIMENTAL
Intervention: High MUFA diet (20% energy; SAFA and PUFA 10% each)
Number of subjects: 28
Study 1639051 — intervention group
Group type: COMPARATOR
Intervention: High SAFA diet
Number of subjects: 28
Study 6208573 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal advance organizer presented to experimental subjects at the beginning of each of six classes.
Number of subjects: 43
Study 6208573 — intervention group
Group type: COMPARATOR
Intervention: Nonorganizing historical information presented to control subjects at the beginning of each of six classes.
Number of subjects: 43
Study 31284871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine (0.3 mg/kg)
Number of subjects: 135
Study 31284871 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Morphine (0.1 mg/kg)
Number of subjects: 135
Study 29696307 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation technique
Number of subjects: 30
Study 29696307 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic technique
Number of subjects: 30
Study 26395786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellphone reminder/recall (R/R)
Number of subjects: 595
Study 26395786 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Health Care Immunization Providers' Training (PHCIPT)
Number of subjects: 595
Study 26395786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cellphone R/R and PHCIPT
Number of subjects: 595
Study 26395786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 595
Study 24509055 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 93
Study 24509055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 22421738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation with fondaparinux sodium
Number of subjects: 64
Study 22421738 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation with fondaparinux sodium + vena cava filter
Number of subjects: 64
Study 20201005 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 400 mg/day
Number of subjects: 62
Study 20201005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 18351423 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive TKA (MIS-TKA)
Number of subjects: 30
Study 18351423 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 30
Study 16471172 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 39